Eoin is an expert in the field of cancer biology with an emphasis on cellular signaling, epigenetics, cellular metabolism, and CRISPR/Cas9 genome editing tools. He has extensive experience in drug discovery in both startup biotech (Integrated Oncology Solutions and Element Genomics) and large pharma (Pfizer and UCB Pharma) settings. He earned his BA in Biology from Virginia Tech and a PhD in Molecular Cancer Biology from Duke University. During his PhD at Duke University, he focused on discovering links between cancer cell metabolism, epigenetics and cancer cell growth. At Pfizer Eoin worked in the Oncology Research Unit studying the mechanisms of resistance to the CDK4/6 inhibitor Ibrance (palbociclib) in breast cancer, Pfizer’s lead oncology asset, and identified novel therapeutic drug combinations. He is experienced in developing cutting-edge functional genomic screens to understand the biology of small molecule drugs and complex cell signaling networks. At Element Genomics (acquired by UCB Pharma 2018) he made significant advances in CRISPR/Cas9 phenotypic screening technology to identify novel drug targets. His passion is in discovering and novel cancer therapies using high-throughput screening technologies with an emphasis on understanding drug mechanisms of action, drug resistance and identifying tumor-specific vulnerabilities.